At PrimeGen, we develop cell therapies based on our proprietary scientific platform, which is backed by invaluable research that spans two decades and is reinforced by a vast portfolio of intellectual property and patents.

We’ve developed proprietary GMP-compliant protocols for cultivating and expanding multipotent and pluripotent stem cells from a variety of tissues sources in a manner that maximizes viability and potency.

We have two cell therapy models currently in the clinical trials preparation phase. Our baseline MSC therapy has multipotent abilities that are valuable to the treatment of a variety of different inflammatory diseases. This allows our operational platform to be scalable and versatile for a range of hepatic, renal, pulmonary and cardiovascular disorders. Our Prime MSC therapies employ patented priming technologies and protocols for jumpstarting and enhancing the anti-inflammatory capabilities of MSCs before patient administration. Both cell therapy models are in clinical trials for the treatment of liver cirrhosis, and are being explored for several other disease models. 

We believe the performance and efficacy of cell therapies can be further enhanced by combining them with other modern medical technologies. We are pioneering the use of a variety of treatments, such as low-level laser and pulsed electromagnetic field therapy for preparing microenvironments for cell therapy, and cell encapsulation for localizing cells to a specific site for targeted cytokine therapy.